Exocrine pancreatic insufficiency (EPI)
Pancreatic disorders have been among the MDL diseases that we focus on for years. In the period 2004 to 2016, Tramedico previously conducted a pancreas with product. In the period 2004 to 2016, Tramedico previously conducted a pancreas enzyme product.
Pantriozyme capsules contain pancreatin, which consists of the pancreatic enzymes lipase, protease, and amylase. These enzymes are used when the pancreas is unable to produce them in sufficient quantities. This condition occurs, for example, in cases of long-standing inflammation of the pancreas (chronic pancreatitis) and cystic fibrosis. The enzymes support digestion, particularly the breakdown of fats by lipase.
Pantriozyme capsules are manufactured in Germany by Nordmark Pharma GmbH, a company with extensive experience in this field. From 2004 to 2016, Nordmark was also the producer of the pancreatic enzyme product previously distributed by Tramedico in the Netherlands.
Products
-
Read more: Pantriozyme
Pantriozyme
Exocrine Pancreatic Insufficiency (EPI) is a condition in which the pancreas does not produce sufficient digestive enzymes. EPI is commonly associated with conditions such as cystic fibrosis, pancreatitis, pancreatic carcinoma, or may occur following pancreatic surgery.
These enzymes are essential for breaking down and absorbing fats, proteins, and carbohydrates from food. Without adequate enzyme production, the body is unable to efficiently absorb nutrients, which can lead to malnutrition and other health complications.
